HuagongsheHuagongshe Chemistry Print Report · For research reference only
4-Bromo-1-isoquinolinamine → 4-(8-((4-tert-butylpiperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)isoquinolin-1-amine
Participants
| Role | Name | HCID | Charge |
|---|---|---|---|
| Reactant | 4-Bromo-1-isoquinolinamine | HCID 311870 | — |
| Reactant | 4-(8-((4-tert-butylpiperidin-1-yl)methyl)-9-methyl-2-(tributylstannyl)-9H-purin-6-yl)morpholine | HCID 59605631 | — |
| Product | 4-(8-((4-tert-butylpiperidin-1-yl)methyl)-9-methyl-6-morpholino-9H-purin-2-yl)isoquinolin-1-amine | HCID 59605564 | — |
Reaction Steps
4-(8-((4-tert-butylpiperidin-1-yl)methyl)-9-methyl-2-(tributylstannyl)-9H-purin-6-yl)morpholine (0.1 g) was reacted with 4-bromoisoquinolin-1-amine via General Procedure D to afford 114 (10 mg) following reverse phase purification. MS (Q1) 515.3 (M)+. 1H NMR (500 MHz, CDCl3) δ 9.02 (d, 1H), 7.94-7.45 (m, 6H), 4.35 (s, 4H), 4.02-3.61 (m, 9H), 2.97 (s, 2H), 2.13 (s, 2H), 1.92-1.52 (m, 5H), 1.52-0.68 (m, 26H)
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| Patent number | US08173650B2 |
| Source dataset | uspto-grants-2012_05 |
| ORD ID | ord-f4a4e1f028c645778380eadb69cdc89e |
| Source note | uspto-grants-2012_05 |